Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multi-Center, uncontrolled phase I/II study in patients with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL)

Trial Profile

An open-label, multi-Center, uncontrolled phase I/II study in patients with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirabrutinib (Primary) ; Prednisolone
  • Indications CNS cancer; Lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms ONO-4059-02
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 12 Dec 2023 Results of post-hoc analyses of the 37-month follow-up data, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 06 Jun 2023 Results of final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 21 Feb 2022 According to a Ono Pharmaceutical media release, based on results from this study the Velexbru approved in Taiwan by the Taiwan Food and Drug Administration (TFDA) for the treatment of adult patients with recurrent or refractory B-cell primary central nervous system lymphoma for which no standard of care has been established.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top